Down syndrome regression disorder, a case series: Clinical characterization and therapeutic approaches.

catatonia corticosteroids down syndrome inflammation personalized medicine trisomy 21

Journal

Frontiers in neuroscience
ISSN: 1662-4548
Titre abrégé: Front Neurosci
Pays: Switzerland
ID NLM: 101478481

Informations de publication

Date de publication:
2023
Historique:
received: 18 12 2022
accepted: 09 02 2023
entrez: 13 3 2023
pubmed: 14 3 2023
medline: 14 3 2023
Statut: epublish

Résumé

Down syndrome (DS) is one of the most frequent genetic disorders and represents the first cause of intellectual disability of genetic origin. While the majority of patients with DS follow a harmonious evolution, an unusual neurodevelopmental regression may occur, distinct from that described in the context of autism spectrum disorders, called down syndrome regression disorder (DSRD). Based on four patients, two males and two females, with age range between 20 and 24, treated at the Reference Center for Rare Psychiatric Disorders of the GHU Paris Psychiatry and Neurosciences [Pôle hospitalo-universitaire d'Évaluation Prévention et Innovation Thérapeutique (PEPIT)], we describe this syndrome, discuss its etiologies and propose therapeutic strategies. DSRD often occurs in late adolescence. There is a sudden onset of language disorders, loss of autonomy and daily living skills, as well as behavioral symptoms such as depression, psychosis, or catatonia. These symptoms are non-specific and lead to an overlap with other diagnostic categories, thus complicating diagnosis. The etiologies of the syndrome are not clearly identified but certain predispositions of patients with trisomy 21 have suggested an underlying immune-mediated mechanism. Symptomatic therapeutic approaches (serotonergic antidepressants, atypical antipsychotics, benzodiazepines) were not effective, and generally associated with poor tolerance. Etiological treatments, including anti-inflammatory drugs and corticosteroids, led to partial or good recovery in the four cases. Early recognition of regressive symptoms and rapid implementation of adapted treatments are required to improve the quality of life of patients and their families.

Identifiants

pubmed: 36908800
doi: 10.3389/fnins.2023.1126973
pmc: PMC9995749
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1126973

Informations de copyright

Copyright © 2023 Bonne, Iftimovici, Mircher, Conte, Louveau, Legrand, Danset-Alexandre, Cannarsa, Debril, Consoli, Krebs, Ellul and Chaumette.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Horm Res Paediatr. 2017;87(3):170-178
pubmed: 28259872
Brain Sci. 2017 May 27;7(6):
pubmed: 28555009
Dev Med Child Neurol. 2019 Jul;61(7):847-851
pubmed: 30548468
J Child Neurol. 2015 Aug;30(9):1147-52
pubmed: 25367918
N Engl J Med. 2020 Jun 11;382(24):2344-2352
pubmed: 32521135
Front Neurol. 2022 Jul 15;13:940175
pubmed: 35911905
Genet Med. 2020 Apr;22(4):767-776
pubmed: 31767984
C R Hebd Seances Acad Sci. 1959 Mar 16;248(11):1721-2
pubmed: 13639368
J Dev Behav Pediatr. 2008 Apr;29(2):89-93
pubmed: 18367994
Pediatrics. 2020 Jun;145(6):
pubmed: 32471843
Front Neurol. 2021 Mar 26;12:621637
pubmed: 33841297
Lancet Neurol. 2021 Nov;20(11):930-942
pubmed: 34687637
Neuropsychiatr Dis Treat. 2019 Sep 20;15:2723-2741
pubmed: 31571888
Neuropsychiatr Dis Treat. 2015 Apr 02;11:941-9
pubmed: 25897230
Nat Rev Dis Primers. 2020 Feb 6;6(1):9
pubmed: 32029743
J Neurodev Disord. 2022 Jun 3;14(1):35
pubmed: 35659536
Curr Opin Psychiatry. 2017 Mar;30(2):102-107
pubmed: 28009725

Auteurs

Sidney Bonne (S)

Centre de Référence pour les Maladies Rares à Expression Psychiatrique, GHU Paris Psychiatrie et Neurosciences, Paris, France.

Anton Iftimovici (A)

Centre de Référence pour les Maladies Rares à Expression Psychiatrique, GHU Paris Psychiatrie et Neurosciences, Paris, France.
Université Paris Cité, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, Paris, France.

Clotilde Mircher (C)

Institut Jérôme Lejeune, Paris, France.

Martine Conte (M)

Institut Jérôme Lejeune, Paris, France.

Cécile Louveau (C)

Centre de Référence pour les Maladies Rares à Expression Psychiatrique, GHU Paris Psychiatrie et Neurosciences, Paris, France.

Adrien Legrand (A)

Centre de Référence pour les Maladies Rares à Expression Psychiatrique, GHU Paris Psychiatrie et Neurosciences, Paris, France.

Charlotte Danset-Alexandre (C)

Centre de Référence pour les Maladies Rares à Expression Psychiatrique, GHU Paris Psychiatrie et Neurosciences, Paris, France.
Université Paris Cité, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, Paris, France.

Costanza Cannarsa (C)

EDRPsy, UMR 5229, Centre National de la Recherche Scientifique (CNRS), Paris, France.

Alexis Debril (A)

Department of Child and Adolescent Psychiatry, Hospital Robert Debré Ap-Hp, Paris, France.

Angèle Consoli (A)

Department of Child and Adolescent Psychiatry, Pitié-Salpêtrière Hospital, Paris, France.
Dimensional Approach of Child and Adolescent Psychotic Episodes, Faculté de Médecine, Sorbonne Université, Paris, France.

Marie-Odile Krebs (MO)

Centre de Référence pour les Maladies Rares à Expression Psychiatrique, GHU Paris Psychiatrie et Neurosciences, Paris, France.
Université Paris Cité, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, Paris, France.

Pierre Ellul (P)

Department of Child and Adolescent Psychiatry, Hospital Robert Debré Ap-Hp, Paris, France.
Immunology-Immunopathology-Immunotherapy (i3), UMRS 959, INSERM, Paris, France.

Boris Chaumette (B)

Centre de Référence pour les Maladies Rares à Expression Psychiatrique, GHU Paris Psychiatrie et Neurosciences, Paris, France.
Université Paris Cité, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, Paris, France.
Department of Psychiatry, McGill University, Montreal, QC, Canada.

Classifications MeSH